Abcam, ab283678, Anti-Trans-Golgi network integral membrane protein 1 antibody [EPR24831-36]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal Trans-Golgi network integral membrane protein 1 antibody. Suitable for ICC/IF, IP, WB, IHC-P, Flow Cyt (Intra) and reacts with Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR24831-36,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse,
Applications:WB, IHC-P, Flow Cyt (Intra), ICC/IF, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Trans-Golgi network integral membrane protein 1 also known by the acronym TGOLN2 or TGN46 is an integral membrane protein that plays a critical role in the sorting and trafficking of proteins. The protein has a molecular mass of about 46 kDa and resides primarily in the trans-Golgi network of eukaryotic cells. It is expressed in various tissues with prominent expression in cells featuring extensive secretory pathways such as liver and pancreatic cells. This positioning enables it to fulfill its role in mediating the transport of proteins from the Golgi apparatus to their specific cellular destinations.
Biological function summary
The protein is involved in maintaining the structure and function of the trans-Golgi network. TGOLN2 works as part of a complex network that includes multiple integral membrane proteins which regulate vesicular trafficking. Its ability to bind with other proteins facilitates the sorting and packaging of secretory proteins which are then dispatched through vesicles. By efficiently working with the cellular machinery TGOLN2 contributes to the proper processing and delivery of proteins essential for cellular function.
Pathways
TGOLN2 significantly integrates in the protein trafficking and glycosylation pathways within cells. It cooperates closely with Kinesin and Dynein motor proteins to move vesicles along cytoskeletal tracks to their correct location. TGOLN2 also interacts with adaptin protein complexes which are important for the selection of cargo proteins destined for delivery to specific compartments. This positioning in pathways makes TGOLN2 an essential factor in ensuring the precise cellular localization of proteins.
Dysregulation of TGOLN2 expression has been linked to certain neurodegenerative disorders and cancers. Altered functioning in TGOLN2 may contribute to diseases like Alzheimer's by influencing the abnormal accumulation of amyloid precursor protein which TGOLN2 is known to interact with. Additionally cancer cells often show altered protein trafficking mechanisms where the disruption of TGOLN2 can impact tumor progression and metastasis. Understanding TGOLN2's interactions may provide insights into the pathogenesis of these conditions offering potential therapeutic avenues.